Exscientia wins the Prix Galien USA 2022 Digital Health Solution Award

Coveted Biopharmaceutical Industry Award Recognizes Company’s AI-Based Precision Medicine Platform

OXFORD, England, October 28, 2022–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) is honored to announce that the company has won the Prix Galien USA 2022 Best Digital Health Solution for its precision medicine platform based on ‘IA. The award was presented Thursday at the Prix Galen Forum in New York. Around the world, the Prix Galien, designed to recognize excellence in scientific innovations that improve human health, is considered the most coveted prize in biopharmaceutical research.

Exscientia is dedicated to designing fundamentally better medicines, faster. The company’s artificial intelligence (AI)-based functional precision medicine platform enables a patient-first approach by integrating primary human tissue samples into early target and drug research. Earlier this year, the landmark EXALT-1 study clinically proved that the next-generation platform, which aims to reinvent the way drugs are discovered and developed, helps select treatments and improves treatment outcomes against the cancer.

EXALT-1 demonstrated the ability of one of Exscientia’s AI-discovered drugs to improve cancer treatment outcomes, marking the first time that a functional precision oncology platform has improved patient outcomes in an interventional clinical study. Today, the living tissue technology used in this study is an essential component of Exscientia’s end-to-end platform, which discovered the first three AI-designed molecules to enter clinical trials. This dramatically reduces the time and cost needed to create new molecules that can become approved drugs.

“Our sincere thanks to the Fondation Galien and Business France for this incredible honour. Exscientia is humbled to receive this accolade and our deepest appreciation goes to our incredible team, whose vision made it all possible,” said Andrew Hopkins, DPhil, Founder and CEO of Exscientia. “This award is recognition of the enormous potential that AI holds to transform the way our industry discovers and develops the right medicine for the right patient. This award recognized the potential of our AI-based precision medicine platform to truly bring personalized medicine to the patient. Soon all medicines will be discovered and developed with the help of AI. At Exscientia, we pride ourselves on leading the way. »

About Exscientia

Exscientia is an AI-powered pharmaceutical technology company committed to discovering, designing and developing the best possible medicines in the fastest and most efficient way. Exscientia has developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to advance small molecules designed with to AI. Our portfolio of internal projects builds on our precision medicine platform in oncology, while our portfolio of partnered projects extends our approach to other therapeutic areas. As pioneers of a new approach to drug creation, we believe that the best scientific ideas can very quickly become the best medicines for patients.

Based in Oxford (England, United Kingdom), Exscientia has offices in Vienna (Austria), Dundee (Scotland, United Kingdom), Boston (Massachusetts, United States), Miami (Florida, United States), Cambridge ( England, United Kingdom) and Osaka (Japan).

For more information, please visit www.exscientia.ai and follow us on Twitter @exscientiaAI.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to the progress of discovery and development of candidate molecules; the timing, progress and data relating to clinical trials of Exscientia’s product candidates; and Exscientia’s expectations regarding anticipated revenues and cash. Any statement describing the Company’s objectives, plans, expectations, financial and other projections, intentions or beliefs constitutes a forward-looking statement and should be considered a statement of risks. These statements are subject to a number of risks, uncertainties and assumptions, including those relating to the impact of the COVID-19 pandemic on the Company’s business, in particular on the scope, progress and strengthening of efforts Exscientia’s product development; the initiation, scope and progress of preclinical studies and ongoing clinical trials conducted by Exscientia and its partners, and their cost ramifications; clinical, scientific, regulatory and technical developments; the process of discovering, developing and bringing to market safe and effective product candidates for use as human therapeutic agents; and the task of building a business dedicated to these product candidates. In light of these risks and uncertainties, as well as other risks and uncertainties described in the “Risk Factors” section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings made from time to time by Exscientia with the SEC (available at https://www.sec.gov/), the events and circumstances discussed in this type of forward-looking statements may not occur, and Exscientia’s actual results may differ materially and adversely from those anticipated or implied by this release. Although Exscientia’s forward-looking statements reflect the good faith judgment of its management, they are based only on facts and factors currently known to the Company. Accordingly, the reader is cautioned not to place undue reliance on these forward-looking statements.

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.

View the source version on businesswire.com: https://www.businesswire.com/news/home/20221028005294/en/


Sara Sherman


Leave a Comment